|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/06/20 Iovance Biotherapeutics, Inc. 10-Q 6/30/20 63:7.7M Toppan Merrill/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.27M
2: EX-10.3 Material Contract HTML 38K
3: EX-10.4 Material Contract HTML 51K
4: EX-31.1 Certification -- §302 - SOA'02 HTML 23K
5: EX-31.2 Certification -- §302 - SOA'02 HTML 23K
6: EX-32.1 Certification -- §906 - SOA'02 HTML 20K
7: EX-32.2 Certification -- §906 - SOA'02 HTML 20K
14: R1 Document And Entity Information HTML 71K
15: R2 Condensed Consolidated Balance Sheets HTML 90K
16: R3 Condensed Consolidated Balance Sheets HTML 40K
(Parenthetical)
17: R4 Condensed Consolidated Statements of Operations HTML 40K
18: R5 Condensed Consolidated Statements of Comprehensive HTML 29K
Loss
19: R6 Condensed Consolidated Statements of Stockholders' HTML 80K
Equity
20: R7 Condensed Consolidated Statements of Cash Flows HTML 84K
21: R8 General Organization and Business HTML 29K
22: R9 Summary of Significant Accounting Policies HTML 143K
23: R10 Cash Equivalents and Short-Term Investments HTML 108K
24: R11 Balance Sheet Components HTML 37K
25: R12 Stockholders' Equity HTML 30K
26: R13 Stock Based Compensation HTML 71K
27: R14 Licenses and Agreements HTML 38K
28: R15 Legal Proceedings HTML 37K
29: R16 Leases HTML 141K
30: R17 Related Party Transactions HTML 22K
31: R18 Subsequent Event HTML 21K
32: R19 Summary of Significant Accounting Policies HTML 173K
(Policies)
33: R20 Summary of Significant Accounting Policies HTML 127K
(Tables)
34: R21 Cash Equivalents and Short-Term Investments HTML 108K
(Tables)
35: R22 Balance Sheet Components (Tables) HTML 36K
36: R23 Stock Based Compensation (Tables) HTML 64K
37: R24 Leases (Tables) HTML 129K
38: R25 General Organization and Business (Details) HTML 44K
39: R26 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash, HTML 38K
Cash equivalents and Restricted Cash (Details)
40: R27 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Loss HTML 28K
per share (Details)
41: R28 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair HTML 25K
value (Details)
42: R29 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 23K
Stock-based compensation expense (Details)
43: R30 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 23K
Stock-based compensation by instrument (Details)
44: R31 Cash Equivalents and Short-Term Investments HTML 26K
(Details)
45: R32 Cash Equivalents and Short-Term Investments - HTML 23K
Short-term investments (Details)
46: R33 CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Cost HTML 33K
and fair value (Details)
47: R34 Balance Sheet Components (Details) HTML 34K
48: R35 Stockholders' Equity (Details) HTML 90K
49: R36 STOCK BASED COMPENSATION - Stock Options (Details) HTML 59K
50: R37 STOCK BASED COMPENSATION - Assumptions (Details) HTML 31K
51: R38 STOCK BASED COMPENSATION - Additional information HTML 104K
(Details)
52: R39 Licenses and Agreements (Details) HTML 69K
53: R40 Legal Proceedings (Details) HTML 51K
54: R41 LEASES - Company's right-of-use asset and lease HTML 28K
liabilities (Details)
55: R42 LEASES - components of lease expenses (Details) HTML 42K
56: R43 LEASES - maturities of the Company's operating HTML 45K
lease liabilities (Details)
57: R44 LEASES - Additional information (Details) HTML 142K
58: R45 RELATED PARTY TRANSACTIONS - Additional HTML 35K
information (Details)
59: R46 Subsequent Event (Details) HTML 23K
61: XML IDEA XML File -- Filing Summary XML 106K
13: XML XBRL Instance -- iova-20200630x10q_htm XML 1.90M
60: EXCEL IDEA Workbook of Financial Reports XLSX 88K
9: EX-101.CAL XBRL Calculations -- iova-20200630_cal XML 113K
10: EX-101.DEF XBRL Definitions -- iova-20200630_def XML 491K
11: EX-101.LAB XBRL Labels -- iova-20200630_lab XML 881K
12: EX-101.PRE XBRL Presentations -- iova-20200630_pre XML 744K
8: EX-101.SCH XBRL Schema -- iova-20200630 XSD 133K
62: JSON XBRL Instance as JSON Data -- MetaLinks 254± 388K
63: ZIP XBRL Zipped Folder -- 0001104659-20-091526-xbrl Zip 351K
 | Download this zipped .zip folder |
| Files: | iova-20200630.xsd iova-20200630_cal.xml iova-20200630_def.xml iova-20200630_lab.xml iova-20200630_pre.xml iova-20200630x10q.htm iova-20200630x10q002.jpg iova-20200630xex10d3.htm iova-20200630xex10d4.htm iova-20200630xex31d1.htm iova-20200630xex31d2.htm iova-20200630xex32d1.htm iova-20200630xex32d2.htm |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/28/24 Iovance Biotherapeutics, Inc. 10-K 12/31/23 95:11M Toppan Merrill Bridge/FA 2/28/23 Iovance Biotherapeutics, Inc. 10-K 12/31/22 78:10M Toppan Merrill Bridge/FA 2/24/22 Iovance Biotherapeutics, Inc. 10-K 12/31/21 79:10M Toppan Merrill Bridge/FA 2/25/21 Iovance Biotherapeutics, Inc. 10-K 12/31/20 84:11M Toppan Merrill Bridge/FA 2/09/21 Iovance Biotherapeutics, Inc. 424B5 1:799K Toppan Merrill/FA 11/05/20 Iovance Biotherapeutics, Inc. 10-Q 9/30/20 62:7.8M Toppan Merrill Bridge/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 6/09/20 Iovance Biotherapeutics, Inc. 8-K:5,9 6/08/20 12:480K Toppan Merrill/FA 5/27/20 Iovance Biotherapeutics, Inc. 8-K:5,8,9 5/27/20 12:508K Toppan Merrill/FA 2/25/20 Iovance Biotherapeutics, Inc. 10-K 12/31/19 88:11M Toppan Merrill/FA |